The company has legally retrieved all intellectual data related to stage 2 clinical trial data, along with all previous data from Hemostemix Israel and the randomized table needed to evaluate ACP-01 clinical trial data in North America and South Africa.
Universal Ibogaine Inc. (UI) (TSXV: IBO) (OTC: IBOGF) hottest stock making heavy profit. Click below link to know more
Potential Healthcare Stocks That Are Making Investors Insane About The Profit
Neuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more
so keep Update your ideas with the new addition of $IBO Update your watch list with the new addition of $IBO Stocks veered from bearish to bullish day by day & leaving investors amazed in the Tsx_v market
Hemostemix recently granted the global field license of use of NCP-01 and its autologous stem cell therapies to PreCerv Inc. its wholly owned subsidiary to aid patients with peripheral and central nervous system conditions.
Universal Ibogaine is working with Health Canada to undertake a planned clinical trial in Canada to demonstrate the safety and efficacy of the Ibogaine treatment protocol for opioid use disorder.
At the Kelburn Clinic, UI is developing a cutting-edge holistic addiction treatment protocol that, when combined with the anticipated ibogaine detox programme, will transform the way we treat addiction and dramatically enhance the lives of individuals and families plagued by addiction.
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." Alike Blue Digital Media’s expertise radar
Universal Ibogaine Inc. CEO made a statement "Our capital markets and investor relations strategy includes the FSE listing. We recently began trading on the OTCQB Exchange in the United States, and curiosity in the UI story is growing in Europe, particularly Germany. With a mushrooming market and interest in psychedelic medications, Germany has a reputation for...
Dr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
Blue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.
$HEM is currently trading on the TSX-V effortlessly at $0.28 with no such loss percentage recorded yet and is expected to rise significantly in the upcoming week effectively.
$HEM have developed and established a firm market cap which has been on the rise steadily since the listing of the stock on TSX-V, currently the cap valuation is $19.773 Million.
Hemostemix disclosed a non-brokered private offering of about 15 million units to shareholders, priced in the context of the market, with each unit consisting of one common share and one common share purchase warrant.
Dr. Alberto Sola, the co-founder of $IBOGF is going to present his latest findings in a panel titled “Ibogaine Hydrochloride and Acute Opioid Detox”.
Hemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from inception, June 11, 2021, to December 31, 2021.
Universal Ibogaine Inc. is a Canadian Life science company trading at TSX-V with the ticker symbol $IBO currently sits at $0.0450 with volume around $25K+. invest now for getting higher return